Financial Performance - The company's revenue for Q1 2025 was CNY 401,482,952.19, representing a year-over-year increase of 1.41% compared to CNY 395,905,330.07 in the same period last year[4] - Net profit attributable to shareholders decreased by 58.29% to CNY 10,907,104.58 from CNY 26,150,321.80 in the previous year[4] - The net profit after deducting non-recurring gains and losses dropped by 70.46% to CNY 7,029,713.48 from CNY 23,794,077.50 year-over-year[4] - Basic and diluted earnings per share fell by 50.00% to CNY 0.02 from CNY 0.04 in the same period last year[4] - Total operating revenue for Q1 2025 was ¥401,482,952.19, a slight increase of 1.46% compared to ¥395,905,330.07 in Q1 2024[26] - Net profit for Q1 2025 was ¥9,622,479.68, down 62.5% from ¥25,691,096.53 in Q1 2024[27] - The company reported a total profit of ¥13,081,988.48 for Q1 2025, down from ¥34,518,629.33 in Q1 2024, a decline of 62.1%[27] Assets and Liabilities - Total assets at the end of the reporting period were CNY 2,173,223,750.91, a decrease of 6.06% from CNY 2,313,498,343.10 at the end of the previous year[5] - Current assets decreased to CNY 958,327,705.52 from CNY 1,080,864,363.47, primarily due to a reduction in cash and inventory[21] - Total liabilities decreased to CNY 406,847,133.40 from CNY 548,716,746.59, indicating improved financial stability[23] - The company's equity attributable to shareholders increased slightly to CNY 1,775,791,250.52 from CNY 1,772,911,604.62[23] Cash Flow - The company reported a net cash flow from operating activities of CNY -97,063,782.94, an improvement from CNY -129,488,834.36 in the previous year[4] - Cash flow from operating activities showed a net outflow of ¥97,063,782.94 in Q1 2025, an improvement from a net outflow of ¥129,488,834.36 in Q1 2024[29] - Cash and cash equivalents at the end of Q1 2025 were ¥123,633,938.76, down from ¥225,990,046.68 at the end of Q1 2024[30] - Investment activities generated a net cash inflow of ¥4,953,107.36 in Q1 2025, contrasting with a net outflow of ¥78,431,446.71 in Q1 2024[30] Expenses - Total operating costs increased to ¥391,483,113.73 in Q1 2025 from ¥363,845,443.70 in Q1 2024, representing a rise of 7.66%[26] - Research and development expenses increased to ¥10,076,572.33 in Q1 2025 from ¥7,328,907.08 in Q1 2024, reflecting a growth of 37.7%[26] - Sales expenses rose significantly to ¥75,040,972.82 in Q1 2025, compared to ¥42,896,126.63 in Q1 2024, marking an increase of 75.3%[26] Business Development - The decline in net profit was primarily attributed to differences in the sales cycle of probiotic beverages during the Spring Festival compared to the previous year, alongside increased expenses from ongoing investments in new business initiatives[8] - The company reported a strong development momentum in Q1 2025, with traditional beverage business stability and significant growth in the emerging probiotic sector[12] - Probiotic food revenue increased by 139.19% year-on-year in Q1 2025, demonstrating remarkable results[15] - E-commerce channel revenue surged by 1,173.33% year-on-year in Q1 2025, driven by market optimization and enhanced industry collaboration[13] - The company launched innovative probiotic beverages, including daily beauty and sleep aid products, which received multiple innovation awards[14] - The company holds a leading position in the domestic ambient yogurt market, focusing on product innovation and channel development[13] - The company has integrated its probiotic business with Yunnan Runying Biotechnology, enhancing the entire industry chain[15] - The company aims to enhance its market competitiveness through continuous innovation and strategic partnerships in the health industry[17] Shareholder Information - The company has a total of 26,969 shareholders at the end of the reporting period, with the top 10 shareholders holding significant stakes[10] - The company’s repurchase account holds 14,660,000 shares, accounting for 2.44% of the total share capital at the end of the reporting period[11] Research and Development - The subsidiary Junyao Runying has over 30,000 strains in its probiotic resource library, focusing on gut health, weight management, and immune regulation[16] - The company has established partnerships with several universities to enhance its R&D capabilities, resulting in the award-winning strain Lp-G18 and the patented CCFM1166 strain[17] Supply Chain and Operations - The integration of supply chain management and big data has improved operational efficiency, optimizing order processing, inventory management, and logistics[18]

Financial Performance - The company reported a net profit attributable to shareholders of -29,116,350.88 RMB for 2024, with a distributable profit of 424,155,504.86 RMB at the end of the reporting period[6]. - The company's operating revenue for 2024 was CNY 1,458,166,483.96, a decrease of 10.77% compared to CNY 1,634,102,031.54 in 2023[24]. - The net profit attributable to shareholders for 2024 was CNY -29,116,350.88, representing a decline of 150.57% from CNY 57,575,881.73 in 2023[24]. - The cash flow from operating activities for 2024 was CNY 32,645,604.62, down 61.95% from CNY 85,795,398.12 in 2023[24]. - The total revenue for the company reached approximately ¥1.45 billion, representing a year-over-year increase of 30.38%[69]. - The gross margin for the overall business was reported at 30.38%, with a year-over-year decrease of 10.87%[69]. - The company achieved total revenue of CNY 1,458,166,483.96, a year-on-year decrease of 10.77%[64]. - The net profit attributable to shareholders was a loss of CNY 29,116,350.88, representing a year-on-year decline of 150.57%[64]. Dividend and Shareholder Returns - A cash dividend of 0.08 RMB per share (before tax) is proposed, amounting to a total of 46,865,920.00 RMB (before tax) based on 585,824,000 shares[6]. - The company aims to maintain a stable dividend distribution policy to protect investors' rights and interests[6]. - The company has implemented a cash dividend policy, with a cumulative cash dividend amount of 132,486,920.00 CNY over the last three accounting years[192]. - The proposed cash dividend for 2024 is 0.08 CNY per share (tax included), with a total cash dividend distribution amounting to 46,865,920.00 CNY based on 585,824,000 shares[189]. Research and Development - In 2024, the company increased its R&D investment by 38% and expanded its R&D team by 19%[36]. - The company increased its R&D investment by 34% in 2024, achieving multiple domestic breakthroughs in the probiotic field, including four international awards for its plant-based Lactobacillus Lp-G18 strain[41]. - The total R&D expenditure amounted to CNY 34,642,214.07, which is 2.38% of total revenue[86]. - The company is investing in new technology development, allocating 100 million yuan towards R&D for enhancing product quality and production efficiency[165]. Market Expansion and Sales Strategy - E-commerce channel sales grew by 177.49% year-on-year in 2024[38]. - The company plans to continue expanding its overseas market presence and improve product quality and service levels[62]. - The company is focusing on new retail ecosystem development and channel construction in new traffic areas, leveraging its existing sales network for omnichannel sales[49]. - The company plans to enhance its e-commerce strategy by optimizing operations and integrating online and offline resources[120]. - The company is exploring digital marketing strategies, achieving over 76 million total exposures through various channels and collaborations with influencers in 2024[43]. Operational Efficiency and Production - The company has established a complete quality system for raw material procurement, ensuring compliance with quality requirements and delivery standards[109]. - The company has integrated several unique functional strains into its product offerings, creating a high technological barrier and developing a core product matrix for future growth[49]. - The company is enhancing its production capabilities through automation and digital management systems to improve efficiency and reduce costs[153]. - The company operates its own factories in Yichang and Quzhou, but faces capacity constraints that limit production during peak seasons[54]. Governance and Management - The company has a governance structure in place that includes a shareholders' meeting, board of directors, and supervisory board, ensuring clear division of responsibilities and improved management efficiency[158]. - The company has approved various resolutions in its shareholder meetings, including financial reports and profit distribution plans, demonstrating active governance and strategic planning[159]. - The management team includes experienced professionals with significant backgrounds in finance and management, enhancing strategic decision-making capabilities[164]. - The company has established a fair and transparent performance evaluation and incentive mechanism for senior management, conducting monthly assessments[197]. Risks and Challenges - There are no significant risks that could materially affect the company's production and operations during the reporting period[10]. - The company is facing risks from intensified market competition and fluctuations in raw material prices, which could impact profit margins[154]. - Consumer confidence has declined due to consumption downgrade, affecting actual demand and company performance; there is a need for product diversification and health-oriented features to maintain competitiveness[156]. - The company has not faced any penalties from securities regulatory agencies in the past three years[173].

证券代码：605388 证券简称：均瑶健康 公告编号：2025-018 湖北均瑶大健康饮品股份有限公司 关于注销 2022 年股票期权激励计划部分股票期权的 公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担责任。 湖北均瑶大健康饮品股份有限公司（以下简称"公司"）于 2025 年 4 月 18 日召开公司第五届董事会第十二次会议和第四届监事会第十次会议，审议通过了 《关于注销 2022 年股票期权激励计划部分股票期权的议案》，现将有关事项说 明如下： 一、公司 2022 年股票期权激励计划已履行的审批程序 1、公司于 2022 年 3 月 4 日召开第四届董事会第十五次会议、第三届监事 会第十二次会议，审议通过了《关于<湖北均瑶大健康饮品股份有限公司 2022 年股票期权激励计划（草案）>及其摘要的议案》等本激励计划相关事项的议案， 关联董事朱航明回避表决，公司独立董事发表了同意意见。具体内容请详见公司 于 2022 年 3 月 5 日刊登于上海证券交易所网站（www.sse.com.cn）的《湖北均 瑶大健康饮品股份有限公司 20 ...

国浩律师(上海) 事务所 关于 湖北均瑶大健康饮品股份有限公司 注销 2022 年股票期权激励计划 部分股票期权的 法律意见书 國浩律師事務所 GRANDALL LAW FIRM 上海市静安区山西北路 99 号苏河湾中心 25-28 楼 邮编: 200085 25-28/F, Suhe Centre, 99 North Shanxi Road, Jing'an District, Shanghai 200085 电话/Tel: +86 21 5234 1668 传真/Fax: +86 21 52433320 网址/Website: http://www.grandall.com.cn 二〇二五年四月 国浩律师(上海)事务所 法律意见书 国浩律师(上海)事务所 关于湖北均瑶大健康饮品股份有限公司 注销 2022 年股票期权激励计划部分股票期权 的法律意见书 致:湖北均瑶大健康饮品股份有限公司 第一节 法律意见书引言 一、 出具法律意见书的依据 本所律师已根据法律意见书出具日以前已经发生或存在的事实和现行法律、 法规,其他规范性文件的有关规定发表法律意见。本所律师仅就中国法律有关的 问题发表法律意见。 本所及经办 ...

均瑶健康（605388）公告，2025年第一季度营收为4.01亿元，同比增长1.41%；净利润为1090.71万元， 同比下降58.29%。 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 证券代码：605388 证券简称：均瑶健康 公告编号：2025-011 湖北均瑶大健康饮品股份有限公司 关于延期披露 2024 年年度报告的公告 湖北均瑶大健康饮品股份有限公司董事会 2025 年 4 月 18 日 1 湖北均瑶大健康饮品股份有限公司（以下简称"公司"）原定于 2025 年 4 月 22 日披露公司 2024 年年度报告。因年报编制工作尚未完成，为进一步完善定 期报告编制和复核的相关工作，确保年度报告披露的真实性、准确性和完整性， 经向上海证券交易所申请，现将公司 2024 年年度报告披露时间延期至 2025 年 4 月 30 日。 公司董事会对本次调整年度报告披露时间给投资者带来的不便致以诚挚的 歉意，敬请广大投资者谅解。 公司指定信息披露网站和媒体为上海证券交易所网站（www.sse.com.cn）及 《上海证券报》《中国证券报》《证券时报》《证券日报》，有关信息以公司在 上述指定网站和媒体刊登的公告为准，敬请广大投资者理性投资，注意投资风险。 特此公告。 ...

湖北均瑶大健康饮品股份有限公司（以下简称"公司"）第四届监事会第 九次会议于 2025 年 4 月 1 日下午在公司会议室以现场结合通讯方式召开，本次 会议通知于 2025 年 3 月 27 日以电子邮件形式送达公司全体监事。本次会议由监 事会主席林乃机先生主持。会议应出席监事 3 人，实际出席监事 3 人。本次会议 的召开符合《公司法》和《公司章程》等有关规定。 二、监事会会议审议情况 （一）审议通过《关于预计公司 2025 年日常关联交易的议案》 证券代码：605388 证券简称：均瑶健康 公告编号：2025-009 湖北均瑶大健康饮品股份有限公司 第四届监事会第九次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、监事会会议召开情况 为有效地保障公司正常生产经营活动的开展，公司拟于 2025 年度与关联方 进行总额不超过 11,950 万元的关联交易。该日常关联交易对公司持续经营能力、 损益及资产状况无不良影响，公司没有对关联方形成较大的依赖。 监事会认为：公司 2024 年度日常关联交易执行履行了合法程 ...

证券代码：605388 证券简称：均瑶健康 公告编号：2025-010 湖北均瑶大健康饮品股份有限公司 关于 2025 年度日常关联交易预计的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ●本次 2025 年度日常关联交易预计事项尚需提交公司 2024 年年度股东大会 审议。 ●日常关联交易对公司的影响：本次日常关联交易预计系公司正常生产经营 需要，定价公允合理，有利于提升公司盈利能力，不存在损害公司及公司股东特 别是中小股东和非关联股东利益的情形，符合公司及股东的利益，不会对公司独 立性产生影响，公司亦不会因此类交易对关联人形成依赖。 一、日常关联交易基本情况 （一）日常关联交易履行的审议程序 2025 年 4 月 1 日，湖北均瑶大健康饮品股份有限公司（以下简称"公司"） 召开第五届董事会第十一次会议、第四届监事会第九次会议，审议通过《关于预 计公司 2025 年日常关联交易的议案》，同意公司 2025 年日常关联交易预计事项。 （三）2025 年度日常关联交易预计金额和类别 2 （二）2024 年 ...

第四届监事会第九次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、监事会会议召开情况 湖北均瑶大健康饮品股份有限公司（以下简称"公司"）第四届监事会第 九次会议于 2025 年 4 月 1 日下午在公司会议室以现场结合通讯方式召开，本次 会议通知于 2025 年 3 月 27 日以电子邮件形式送达公司全体监事。本次会议由监 事会主席林乃机先生主持。会议应出席监事 3 人，实际出席监事 3 人。本次会议 的召开符合《公司法》和《公司章程》等有关规定。 证券代码：605388 证券简称：均瑶健康 公告编号：2025-009 湖北均瑶大健康饮品股份有限公司 （一）审议通过《关于预计公司 2025 年日常关联交易的议案》 为有效地保障公司正常生产经营活动的开展，公司拟于 2025 年度与关联方 进行总额不超过 11,950 万元的关联交易。该日常关联交易对公司持续经营能力、 损益及资产状况无不良影响，公司没有对关联方形成较大的依赖。 监事会认为：公司 2024 年度日常关联交易执行履行了合法程序，且体现了 诚信、公平 ...

证券代码：605388 证券简称：均瑶健康 公告编号：2025-008 湖北均瑶大健康饮品股份有限公司 变更签字注册会计师及项目质量复核人员的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 湖北均瑶大健康饮品股份有限公司（以下简称"公司"）于 2024 年 8 月 22 日召开第五届董事会第八次会议，审议通过了《关于聘任公司 2024 年度审计机 构的议案》，同意聘任中审众环会计师事务所（特殊普通合伙）（以下简称"中审 众环"）担任本公司及下属子公司 2024 年度的财务审计机构和内部控制审计机 构，聘用期限为 1 年。该议案已经公司 2024 年第一次临时股东大会审议通过。 具体内容详见公司于 2024 年 8 月 26 日于上海证券交易所网站（www.sse.com.cn） 披露的《湖北均瑶大健康饮品股份有限公司关于聘任公司 2024 年度审计机构的 公告》（公告编号：2024-046）。 公司近日收到中审众环《关于变更湖北均瑶大健康饮品股份有限公司签字注 册会计师及项目质量复核人员的函》，现就具体情况公告如下： 一 ...